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Title: Calculating individual lifetime effective risk from initial mean glandular dose arising from 
the first screening mammogram 
Abstract 
Objectives: To use the initial mean glandular dose (MGD) arising from the first screening 
mammogram to estimate the individual total screening lifetime effective risk. 
Methods: Organ doses from FFDM screening exposures (craniocaudal and mediolateral oblique 
for each breast) were measured using a simulated approach, with average breast thickness and 
adult ATOM phantoms, on 16 FFDM machines. Doses were measured using TLDs 
accommodated inside the ATOM phantom; examined breast MGD was calculated. Total 
effective risk during a client’s lifetime was calculated for 150 screening scenarios of different 
screening commencement ages and frequencies. For each scenario, a set of conversion factors 
were obtained to convert MGD values into total effective risk. 
Results: For the 16 FFDM machines, MGD contributes approximately 98% of total effective 
risk. This contribution is approximately constant for different screening regimes of different 
screening commencement ages. MGD contribution remains constant but the risk reduced because 
the radio-sensitivity of all body tissues, including breast tissue, reduces with age. Three sets of 
conversion factors were obtained for three screening frequencies (annual, biennial, triennial). 
Three relationship graphs between screening commencement age and total effective risk, as 
percentages of MGD, were created. 
Conclusions: Graphical representation of total risk could be an easy way to illustrate the total 
effective risk during a client’s lifetime. Screening frequency, commencement age, and MGD are 
good predictors for total effective risk generating more understandable data by clients than 
MGD.  
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Introduction 
Breast radiation dose arising from mammography has reduced from approximately 150 mGy for 
film to <2 mGy for full field digital mammography (FFDM) [1]. Incident radiation exposure 
(Roentgens) at the breast surface and entrance surface dose (ESD) were the early quantities used 
to determine the radiation risk from mammography [2]. Since mammography uses low energy X-
ray photons, the radiation dose inside the breast rapidly reduces as the depth increases [3]. 
Accordingly, different quantities have been suggested as measures for mammographic radiation 
risk, these include midline breast dose and total breast energy [2]. In 1976, work by Karlsson, 
Nygren, Wickman, and Hettinger [4] proposed the use of breast glandular tissue radiation dose as 
a measure for mammographic radiation risk. By 1987, the ICRP recommended mean glandular 
dose (MGD) as the measure for breast dosimetry [2]. 
MGD is fundamentally related to target/filter combination (radiation spectrum), X-ray tube 
output (kV, mA, and time), breast density (glandularity) and breast size (compressed breast 
thickness) [3, 5, 6]. Direct estimation of MGD is difficult and it has to be calculated from 
multiplying the incident air kerma by conversion factors that are obtained from Monte Carlo 
mathematical simulations [7]. The main limitation of MGD calculations using conversion factors 
is that during the Monte Carlo simulations a homogenous breast phantom, comprising comprised 
of a uniform distribution of glandular tissue within fatty tissue, of different breast densities was 
used. As concluded by Sechopoulos et al. [8], the use of this homogenous phantom results in 
significant MGD overestimation. The highest MGD overestimation values were recorded at low 
photon energies; overestimation decreases as the photon energy increases. Sechopoulos’s work 
agrees with that of Dance et al. [9], who reported that the use of conversion factors may result in 
as much as a 43% difference in calculated MGD due to glandular tissue spatial distribution. 
Accordingly, Geeraert et al. [10] calculated MGD for six breast phantoms with different 
glandular tissue distributions and different MGD values were subsequently recorded for the 
phantoms. Geeraert et al. [10] suggested the use of total energy imparted in glandular tissue 
(GIE) instead of MGD. 
Mammographic radiation dose to organs other than the examined breast is usually assessed by 
the use of Monte Carlo software with mathematical heterogeneous human body phantoms. 
Within these phantoms, body tissues and organs are mathematically described to consider their 
shape, size and location. Radiation doses are calculated by determining the average radiation 
energy imparted to each organ.  
Sechopoulos et al. [11] utilised the Geant4 Monte Carlo toolkit to simulate four-view film-screen 
mammography. Sechopoulos et al. estimated the radiation dose to all body tissues other than 
breast. They concluded that the doses were extremely small and that the Rh/Rh target/filter 
combination resulted in higher organ doses than those from Mo/Mo and Mo/Rh target/filter 
combinations. They also found that the second and third highest radiation dose, after the 
examined breast, was received by the pectoral muscle and contralateral breast, respectively [11]. 
Sechopoulos and Hendrick [12] estimated the radiation dose  received by the thyroid gland 
during mammography. They considered the thyroid dose to be negligible in regard to radiation-
induced cancer because four-view mammography would result in 1 thyroid cancer case per 166 
million women imaged. Sechopoulos and Hendrick [12] also argued that the use of a thyroid 
shield may result in discomfort to women and interfere with positioning which may cause image 
artifacts. Leidens et al. [13] used the Monte Carlo PENELOPE toolkit to estimate lung, heart and 
red bone marrow radiation dose during standard cranio-caudal (CC) mammography with film-
screen systems. They reported that only the lung received a considerable radiation dose (0.14% 
of the examined breast dose), while doses to the heart (0.033%) and bone marrow (0.0013%) 
were negligible [13].  
A study by Whelan et al. [14] used thermo-luminescent dosimeters (TLDs) to measure radiation 
dose received by women’s skin overlying the thyroid during standard 4 view screening 
mammography and diagnostic mammography. This study concluded that the average measured 
thyroid dose, which was 0.04 mGy, was insignificant compared to the 4 mGy dose received by 
the breast. Hatziioannou et al. [15] also utilised TLDs accommodated inside an upper body 
anthropomorphic Lucite phantom, comprised of Perspex slices designed to simulate female body 
contour. This was performed to investigate the in vivo measurement of dose to the breast, 
sternum red bone marrow (SRBM), thyroid, liver, lung, stomach, and oesophagus during 4 view 
screening mammography using a Giotto mammography machine (Mo/Mo target/filter). They 
found that breast dose contributes over 98% of the overall effective dose. SRBM and thyroid 
receive a radiation dose between 0.4-1.27 and 0.05-0.17 µGy/mAs, respectively, and the other 
organ doses were negligible [15]. The main limitations of Hatziioannou’s study were that the 
simulated mammographic positions were CC and ML (90o angle) for each breast, and the 
homogenous Lucite phantom was not a good simulator of the different body tissues. 
Overall, there is a growing need for obtaining an easy and accurate way to determine the risk of 
radiation-induced cancer from screening mammography. This is particularly useful for screening 
justification and risk-benefit evaluation. Total effective risk during female lifetime is the 
recommended quantity reported by M.Ali et al. [16, 17]. Since the breast tissue receives the 
highest radiation dose, MGD from initial mammogram can be considered to accommodate 
variations amongst different FFDM machines. However, M.Ali et al. [16] have not considered 
MGD variations in their published mathematical model. Accordingly, this work aims to refine 
M.Ali et.al’s model by deriving a woman’s total effective risk from MGD from the initial 
mammogram in addition to screening commencement age and frequency. 
Materials and Methods  
Sixteen UK National Health Service Breast Screening Programme (NHSBSP) FFDM machines 
were included in this study. Machine quality control met NHSBSP standards (beam alignment, 
detector performance, automatic exposure control (AEC), image display monitors, image display 
printers, image quality, and radiation dose) [18]. Machines included 4 manufacturers: 5 Hologic 
(3 Selenia, 2 Selenia Dimensions), 8 GE (Seno Essential), 2 machines Siemens (Mammomat 
Inspiration) and 1 Giotto. Automatic exposure control is used to expose a PMMA-Polyethylene 
breast phantom on each machine. 
Incident air kerma for the PMMA-Polyethylene phantom was multiplied by Dance’s conversion 
factors [7] to obtain MGD for each machine. To replicate the compressed breast thickness and 
shape accurately, two breast phantoms were utilised. A semicircular phantom (95 mm diameter) 
with 32.5 mm thick PMMA and 20.5 mm thick polyethylene was used to simulate compressed 
breast in CC projection. A 150 mm X 100 mm rectangular phantom (32.5 mm thick PMMA and 
25.5 mm thick polyethylene) was utilised to simulate the compressed breast in MLO projection.   
Small (0.125 X 0.125 X 0.035 inches) tissue equivalent (atomic number for TLDs = 8.04 
compared to that of soft tissue = 7.42) TLDs were placed inside an adult anthropomorphic 
ATOM dosimetry phantom [19] to measure organ dose. Absorbed radiation dose for organs was 
calculated by averaging the TLD values within each organ. The numbers of TLDs used for each 
organ are listed in Table (1), the number is consistent with other researchers [20]. 
Table (1) Number of TLDs utilised for organ dose measurements (n=280).    
Organ No. of TLDs Organ No. of TLDs 
Adrenal 2 Pancreas  5 
Brain 11 Pelvis BM* 17 
Clavicle BM* 4 Ribs BM* 18 
Cranium BM* 4 Salivary glands 6 
Cervical spine BM* 2 Scapulae BM* 16 
Gall bladder 5 Spleen  12 
Heart  2 Sternum BM* 4 
Intestine  16 Stomach  14 
Kidneys  16 Thoraco-lumbar spine BM* 8 
Liver  29 Thymus  4 
Lungs  36 Thyroid  6 
Mandible BM* 6 Urinary Bladder (UB) 13 
Oesophagus  3 Uterus 3 
Ovaries  2 Contralateral breast (8 for each side) 16 
*BM = bone marrow. 
 
 
Effective risk was calculated for females aged 25-75 years, the earliest and the latest possible 
ages of screening mammography, using Brenner’s equation  [21]. 
R=∑rTHT 
Where R is the effective risk, rT is the lifetime attributable risk (LAR) of radiation-induced 
cancer for tissue T per unit equivalent dose to that tissue, and HT is the equivalent dose received 
by tissue T. 
The lifetime attributable cancer risk of different tissues (rT) were taken from BEIR VII – Phase 2 
report of  National Academy of Sciences (NAS) [22]. Since these values are only presented for 
each decade of female age, they were plotted graphically against age in order to extrapolate an 
approximate value for each year of female life using a linear relationship between decades. 
Finally, total effective lifetime risk, during female lifetime, for different screening 
commencement ages (25-74 75 years) and for three different screening frequencies (annual, 
biennial, and triennial) were calculated, using the method described by M.Ali et al. [16].  
Since all other body tissue doses are responsible for only 2% and the examined breast radiation 
dose is responsible for approximately 98% of the radiation risk, the relationship between MGD 
and total effective risk for each scenario was established using the data from the 16 FFDM 
machines to accommodate the effect of MGD variations between different FFDM on a woman’s 
total effective risk. Relationship graphs, between screening commencement age and total 
effective risk, were then modified to demonstrate the relationship between screening 
commencement age and the MGD conversion factor for total effective risk.  
Results 
For the sixteen machines, the examined breast received the highest radiation dose, where total 
MGD from one screening visit (for both CC and MLO projections) ranged between 1.678 mGy 
and 2.806 mGy with a mean (95% confidence interval (CI)) of 2.019 (1.871-2.166) mGy (Table 
2). All machines showed MLO MGD to be higher than CC. However, MGD variation between 
MLO and CC differed amongst the 16 machines. 
Table (2) Examined breast MGD for the sixteen FFDM machines. 
Machine 
number 
MGD (mGy) Total MGD 
(mGy) CC view MLO view 
1 1.160 1.271 2.431 
2 1.050 1.273 2.323 
3 0.843 1.164 2.007 
4 0.811 1.082 1.893 
5 0.927 1.082 2.009 
6 0.825 0.949 1.774 
7 1.169 1.637 2.806 
8 0.983 1.219 2.202 
9 0.854 0.977 1.831 
10 1.060 1.071 2.131 
11 0.825 0.853 1.678 
12 0.921 1.055 1.976 
13 0.918 0.941 1.859 
14 0.930 0.961 1.891 
15 0.787 0.969 1.756 
16 0.771 0.959 1.730 
Mean  
(95% CI) 
0.927  
(0.865-0.989) 
1.091  
(0.998-1.185) 
2.019 
(1.871-2.166) 
 
In general, the three highest organ doses, after the examined breast, are the contralateral breast, 
sternum red bone marrow and thyroid, in descending order, respectively. The organs which 
received an average radiation dose of ≥0.1 µGy are presented in Table (3) as a percentage of the 
MGD. 
 
 
Table (3) Mean organ doses for the sixteen FFDM machines (4 projections) along with their 
percentages in relation to the average examined breast MGD. 
Organ 
Radiation dose, 
mean (SD), µGy 
Organ dose percentages of 
MGD, mean (SD) 
Brain  0.91 (1.21) 0.05 (0.07) 
Salivary  2.79 (0.93) 0.14 (0.05) 
Thyroid  9.45 (3.05) 0.47 (0.13) 
Oesophagus  0.26 (0.21) 0.01 (0.01) 
Thymus  2.43 (1.23) 0.12 (0.06) 
Heart  0.39 (0.23) 0.02 (0.01) 
Lung  3.06 (1.06) 0.15 (0.05) 
Liver  0.69 (0.29) 0.03 (0.01) 
Gall bladder 0.19 (0.16) 0.01 (0.01) 
Adrenals  0.10 (0.14) 0.01 (0.01) 
Stomach  0.42 (0.21) 0.02 (0.01) 
Cranium (BM) 1.56 (1.39) 0.08 (0.08) 
Mandible (BM) 2.79 (0.93) 0.14 (0.05) 
Cervical spine (BM) 0.30 (0.34) 0.02 (0.02) 
Clavicles (BM) 9.25 (5.25) 0.45 (0.24) 
Scapulae (BM) 0.17 (0.14) 0.01 (0.008) 
Sternum (BM) 19.07 (6.12) 0.942 (0.25) 
Ribs (BM) 3.57 (1.31) 0.18 (0.05) 
Contralateral breast 28.75 (8.54) 1.42 (0.35) 
Examined breast (MGD) 2018.50 (300.33) 100.00 
 
If organ radiation doses resulting from screening mammography are considered to be constant 
during a female’s lifetime, the changes in effective risk during a female’s lifetime are only 
dependent on LAR reduction with age (Table 4). 
 
 
 
  
 
 
Table (4) Mean calculated effective risk values for the sixteen FFDM machines for each year of 
female life with 95% CI. 
Age 
(year) 
Effective lifetime risk (case/106) Age 
(year) 
Effective lifetime risk (case/106) 
Mean 95% CI Mean 95% CI 
25 70.00 64.88 - 75.12 51 14.10 13.07 - 15.13 
26 66.38 61.53 - 71.24 52 12.93 11.99 - 13.88 
27 62.77 58.18 - 67.36 53 11.82 10.96 - 12.69 
28 59.16 54.83 - 63.48 54 10.76 9.98 - 11.55 
29 55.54 51.48 - 59.60 55 9.76 9.04 - 10.47 
30 51.93 48.13 - 55.72 56 8.81 8.16 - 9.45 
31 48.59 45.04 - 52.15 57 7.91 7.33 - 8.49 
32 46.36 42.97 - 49.75 58 7.06 6.54 - 7.58 
33 44.18 40.95 - 47.41 59 6.27 5.81 - 6.73 
34 42.06 38.98 - 45.13 60 5.53 5.12 - 5.93 
35 39.99 37.06 - 42.91 61 4.84 4.49 - 5.20 
36 37.97 35.19 - 40.74 62 4.21 3.90 - 4.52 
37 36.00 33.37 - 38.63 63 3.63 3.36 - 3.89 
38 34.09 31.60 - 36.58 64 3.10 2.87 - 3.33 
39 32.23 29.88 - 34.59 65 2.63 2.44 - 2.82 
40 30.43 28.20 - 32.65 66 2.21 2.05 - 2.37 
41 28.68 26.58 - 30.78 67 1.84 1.71 - 1.98 
42 26.98 25.01 - 28.95 68 1.53 1.41 - 1.64 
43 25.34 23.48 - 27.19 69 1.27 1.17 - 1.36 
44 23.75 22.01 - 25.48 70 1.06 0.98 - 1.14 
45 22.21 20.58 - 23.83 71 0.90 0.84 - 0.97 
46 20.72 19.21 - 22.24 72 0.80 0.74 - 0.86 
47 19.29 17.88 - 20.70 73 0.75 0.70 - 0.81 
48 17.91 16.60 - 19.22 74 0.75 0.70 - 0.81 
49 16.59 15.38 - 17.80 
75 0.75 0.69 - 0.80 
50 15.32 14.20 - 16.44 
 
The graphical presentation of the relationship between screening commencement age (X-axis) and 
average total effective risk (Y-axis) for the sixteen FFDM machines is demonstrated in Figure (1). 
This was based on the method described by M.Ali et al. [16]. In this figure the cessation age of 
screening mammography is set at a constant level (75 years old).  
 
Figure (1) Represents the relationship between the total effective risk and the screening 
commencement age of different screening frequencies.  
 
Using the data of sixteen FFDM machines, 450 relationship graphs were established to 
investigate the relationship between MGD and total effective risk of each screening scenario, for 
specific screening commencement ages and frequencies (Figure 2 for annual screening 
commence at 25 year). The relationship between MGD (µGy) and the total effective risk 
(case/106) resulted in a set of conversions factors (case/106/µGy) (Table 5). 
 
Figure (2) Relationship between MGD and total effective risk of the sixteen FFDM machines 
resulting from annual screening mammography commencing at 25 years old. 
 
 
 
 
 
 
 
 
 
 
 
 
 Table (5) Conversion factors between total effective risk of the screening programme and MGD 
Commencement 
age (year) 
Conversion factor 
% MGD (case/106/µGy) Commencement 
age (year) 
Conversion factor 
% MGD (case/106/µGy) 
Annual Biennial Triennial Annual Biennial Triennial 
25 54.48 28.13 19.33 51 6.20 3.29 2.33 
26 51.01 26.35 18.15 52 5.51 2.91 2.05 
27 47.73 24.67 17.00 53 4.86 2.59 1.83 
28 44.62 23.06 15.87 54 4.28 2.27 1.63 
27 41.68 21.56 14.86 55 3.75 2.01 1.41 
30 38.93 20.13 13.89 56 3.26 1.74 1.24 
31 36.36 18.81 12.93 57 2.83 1.53 1.09 
32 33.95 17.56 12.11 58 2.43 1.30 0.92 
33 31.66 16.40 11.32 59 2.08 1.13 0.81 
34 29.47 15.26 10.53 60 1.77 0.95 0.70 
35 27.38 14.21 9.81 61 1.50 0.82 0.57 
36 25.40 13.17 9.13 62 1.26 0.68 0.5 
37 23.52 12.23 8.44 63 1.05 0.58 0.43 
38 21.74 11.29 7.83 64 0.87 0.47 0.33 
39 20.05 10.44 7.25 65 0.72 0.40 0.29 
40 18.45 9.60 6.66 66 0.59 0.31 0.25 
41 16.94 8.85 6.14 67 0.48 0.27 0.18 
42 15.52 8.10 5.65 68 0.39 0.20 0.16 
43 14.19 7.43 5.15 69 0.31 0.18 0.14 
44 12.93 6.76 4.72 70 0.25 0.13 0.09 
45 11.75 6.17 4.31 71 0.20 0.12 0.08 
46 10.65 5.58 3.90 72 0.15 0.08 0.08 
47 9.63 5.07 3.54 73 0.11 0.07 0.04 
48 8.67 4.56 3.21 74 0.07 0.04 0.04 
49 7.78 4.11 2.87 
75 0.04 0.04 0.04 
50 6.96 3.67 2.59 
When using this table to calculate total effective risk the commencement age and frequency 
of screening examinations must be selected, and the relevant conversion factor can then be 
multiplied by the MGD (µGy). For example, for a woman attending annual screening 
mammography commencing at 40 years old, she would have a total effective risk of 18.45% 
of her MGD (µGy); for a 2500 µGy MGD the total effective risk is 2500 X 18.45% = 461 
cases/106   
 
The conversion factors listed in Table (5) enable total effective risk to be obtained for any 
screening programme, for any screening commencement age and frequency, whilst considering 
individual MGD. MGD would be derived from the initial screening mammogram. Consequently, 
the graphs used in Figure (1) have been further refined to generate the graphs as illustrated in 
Figure (3); the modified graphs allow determination of the appropriate conversion factor. 
 
Figure (3) Relationship between total effective risk as a percentage of MGD and the screening 
commencement age for different screening frequencies.  
Discussion 
For the sixteen FFDM machines the total MGD (for both CC and MLO projections) ranged 
between 1.678 mGy (machine 11) and 2.806 mGy (machine 7) with a mean (95% CI) value of 
2.019 (1.871 - 2.166) mGy (Table 2). These MGD values are lower than expected for a standard 
breast (with 53 mm thickness and 50% glandularity) because they were calculated for breasts 
with 29% glandularity (without the use of breast composition correction factor, c53 factor). This 
factor is derived from Monte Carlo simulation to convert the MGD from a 29% glandularity 
phantom to 50% glandularity of standard breast. This was undertaken in order to make both the 
calculated MGD and measured organs dose consistent for 29% breast glandularity, which was 
simulated by a PMMA-polyethylene phantom. The standard breast composition recommended 
by mammographic international protocols has 50% glandularity [6, 23]. However, as reported by 
Yaffe  et al. [24], breast glandularity used in this work (29%) represents the most common breast 
density. Yaffe et al. [24] found that only 5% of 2831 Canadian women studied had more than 
45% breast density. 
The organ doses in our work are higher than those estimated by Monte Carlo simulations in 
previous publications. The main reason behind this is likely to be due to the limitations inherent 
within mathematical phantoms used within Monte Carlo simulations [25]. For instance, the 
measured contralateral breast radiation dose, which was 1.419 ± 0.346 % (mean ± SD) of 
examined breast MGD, was approximately as three times that estimated by Sechopoulos  et al. 
[11];  Sechopoulos used Monte Carlo simulation. Also, there is a lower estimated radiation dose 
to clavicular bone marrow (0.09 % and 0.04% of MGD for CC and MLO projections compared 
to 0.451 ± 0.241% MGD ; mean ± SD) and sternum bone marrow (0.49% and 0.23%  MGD for 
CC and MLO projections compared to  0.942 ± 0.251%  MGD). The measured thyroid dose in 
our work was approximately 10 times that estimated by Sechopoulos and Hendrick [12] which 
have been obtained using Monte Carlo simulation. However, ribs bone marrow and lung 
radiation dose was comparable with that reported by Sechopoulos  et al. [11] and Leidens, Goes, 
and Nicolluci [13].  
Despite the large variation of MGD amongst the sixteen FFDM machines (1.678 - 2.806 mGy), 
its contribution to effective risk is fairly constant. This can be explained by the fact that the high 
MGD is usually associated with high organ doses. Since the breast tissue is radio-sensitive and 
that it received the highest radiation dose, MGD can be seen to be directly related to radiation 
[mammographic] effective lifetime risk. The relationship between MGD and total effective 
lifetime risk for different screening scenarios is related to screening commencement age and 
frequency (assuming constant screening cessation age, at 75 years old). This is clearly seen in 
Table (5), where different relationship factors are reported for different screening scenarios. 
Using Figure (3), it becomes possible to obtain the total effective risk of any screening 
programme, for specific screening commencement ages and frequencies, whilst considering 
individual MGD. MGD is being derived from the initial mammogram from any FFDM machine. 
For a woman attended screening mammography within NHSBSP (triennial screening 
commences at 47 years old), her total recorded MGD (for both CC and MLO views) was 3.55 
mGy (3550 µGy). The resultant total effective risk for this woman would be 142 case/106 (4% 
MGD) as derived from Figure (3). 
The total effective risk data obtained in our work is consistent with previously published work. 
For 3.7 mGy MGD, Yaffe and Mainprize [26] found that the total risk of radiation-induced 
breast cancer from annual screening mammography between 40 and 49 years was 590 cases/106. 
In our work for 2.019 mGy MGD the total effective risk of the same screening regimen was 
found to be 224.21 cases/106. Similarly for the same MGD (3.7 mGy), Hendrick [27] reported 
that the incidence of breast cancer resulting from annual screening between 25 - 80 years was 
2040 cases/106. For 2.019 mGy MGD obtained in our work, 1121.36  cases/106 may develop 
cancer due to annual screening mammography between 25 -75 years. The screening 
mammography radiation risk from the UK recommendation was evaluated by Warren, Dance, 
and Young (2016). They found that it ranges between 30.7 and 61.2 cases/106/mGy of MGD. 
This is comparable to that obtained by our work; 77.79 cases/106 for 2.019 mGy. 
Further work is required to include breast density reduction which occurs with age because this 
may result in a continuous reduction in woman’s MGD with age. Accordingly, the extracted total 
effective risk from our work may be slightly exaggerated and should be considered when 
interpreting our data. Generated data from our work is applicable for average breast only. Other 
breast thicknesses and densities should be considered in future work.  
 
Conclusion 
MGD is a primary factor affecting total effective risk as it results in up to 98% of screening 
mammography total effective risk. The addition of MGD variation to the model established by 
M.Ali et al. [16] refines the model by increasing its accuracy and makes it applicable for 
different MGD values of different FFDM machines.  Accordingly, it becomes possible to 
calculate total effective risk for any woman by using MGD from the initial mammogram.   
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